<DOC>
	<DOCNO>NCT02190227</DOCNO>
	<brief_summary>The purpose study determine optimal time use Tumor RNA Disruption Assay ( RDA ) predictor pathological complete response ( pCR ) patient breast cancer treat neoadjuvant chemotherapy . This important early non-responders identify , great impact reduce side effect ineffective treatment . The study hypothesis RDA score accurately predict tumor response one cycle chemotherapy .</brief_summary>
	<brief_title>RNA Disruption Assay ( RDA ) Response Prediction Neoadjuvant Chemotherapy Breast Cancer Treatment</brief_title>
	<detailed_description>This prospective clinical trial determine tumor RDA score predict pCR first , second , third cycle chemotherapy woman breast cancer treat neoadjuvant therapy . Tumor RDA score also measure first dose new chemotherapy agent residual palpable disease present . Data collect accrual target 30 patient meet . All patient undergo core needle biopsy breast tumor analysis ER , PR , HER-2-Neu receptor . Patients receive neoadjuvant therapy recommend treating physician . All chemotherapy regimens acceptable participation study . Usually , regimens 6 8 cycle , often switch chemotherapy regimens 3 4 cycle . Evaluation tumor size determine 2 axis tumor measurement perform prior , chemotherapy treatment . The Tumor RDA score evaluate perform fine needle aspiration ( FNA ) biopsies local anesthetic , tumor clinically palpable , first , second , third cycle chemotherapy . Tumor RDA score also determine palpable tumor present first cycle second chemotherapy agent .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Patients must female . Patients must 18 year age old . Patients stage I , II , III breast cancer great equal 2 cm clinical examination . Patients biopsy proven invasive breast cancer diagnose core needle biopsy Patients chemotherapy radiotherapy na√Øve treatment current breast cancer . Patients accept undergo neoadjuvant chemotherapy . Patients bilateral breast cancer eligible . Patients understand , accept , sign approve write consent form . Patients need consent part study . Patients one follow condition ineligible study : Patients previous surgery , chemotherapy radiotherapy current breast cancer Patients pregnant breast feeding . Psychiatric addictive disorder condition social factor may preclude patient meeting study requirement .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Neoadjuvant</keyword>
	<keyword>RNA Disruption Assay</keyword>
	<keyword>Biopsies</keyword>
	<keyword>Response</keyword>
</DOC>